Cinnarizine + domperidone

Generic Medicine Info
Hypersensitivity. Parkinson's disease. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone or chronic admin or for prophylaxis of postoperative nausea and vomiting. Neonates, children.
Special Precautions
Hypotension. May impair ability to drive or operate machinery. Pheochromocytoma; renal or hepatic impairment; risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy, lactation; elderly.
Adverse Reactions
Extrapyramidal symptoms sometimes associated with severe depression. Drowsiness, headache, GI upsets, unsteadiness, headache; rarely skin and hypersensitivity reactions, dry mouth, thickened resp depression, blurred vision, urinary difficulty or retention, constipation and increased gastric reflux, fatigue. Hypolipidaemic effect, extrapyramidal reactions, galactorrhoea, gynaecomastia; lassitude, decreased libido, skin rash, itch.
Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CVS disease or hypokalaemia, patients on cancer chemotherapy. Seizures, hypertensive crisis in patients with phaeochromocytoma.
Drug Interactions
CNS depressant effect of cinnarizine is enhanced with alcohol. Domperidone reduces absorption of oral digoxin. It increases absorption of aspirin, paracetamol and oral diazepam. Enhances CNS depression by phenothiazine. Antimuscarinic agents and opioids antagonise GI effects. Prolongs suxamethonium-induced neuromuscular blockade.
CIMS Class
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Disclaimer: This information is independently developed by CIMS based on cinnarizine + domperidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in